Durable responses to immunotherapy have been noted in patients with MSS tumors who harbor high tumor mutational burden or have proofreading mutations such as POLE mutations or upregulated PD-L1 expression.30,31,32 Factors affecting durable response in patients with MSS tumors warrant further investigation. This evidence concerns the gene POLE and neoplasm.